Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer

Antzeko izenburuak

• Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
  nork: Botting, Gregory M., et al.
  Argitaratua: (2015)
• A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
  nork: Miyoshi, Seigo, et al.
  Argitaratua: (2015)
• Comparison of Epithelial Mesenchymal Transition Mediated Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer Cell Lines with Wild Type EGFR and Mutant Type EGFR
  nork: Iderzorig, Tsatsral, et al.
  Argitaratua: (2018)
• Combination Therapy With MET Tyrosine Kinase Inhibitor and EGFR Tyrosine Kinase Inhibitor in Patients With MET-Overexpressed EGFR-Mutant Lung Adenocarcinoma
  nork: Jia-Jun Wu, MD, et al.
  Argitaratua: (2025-06-01)
• Role of the ABL tyrosine kinases in the epithelial–mesenchymal transition and the metastatic cascade
  nork: Luttman, Jillian Hattaway, et al.
  Argitaratua: (2021)